Jacobs Levy Equity Management
PGNX

Jacobs Levy Equity Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-88,400
Closed -$381K – 939
2014
Q2 		$381K Sell
88,400
-50,600
-36% -$193K 0.01% 678
2014
Q1 		$569K Buy
+139,000
New +$711K 0.01% 650
2013
Q4 		– Sell
-48,100
Closed -$241K – 1068
2013
Q3 		$241K Sell
48,100
-43,000
-47% -$233K ﹤0.01% 834
2013
Q2 		$406K Buy
+91,100
New +$409K 0.01% 765

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jacobs Levy Equity Management's PGNX Position: Q3 2014 in Review

Jacobs Levy Equity Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2014, closing a stake of 88,400 shares — an estimated $381K sold.

Jacobs Levy Equity Management first reported a position in PGNX in Q2 2013 and held it in 4 quarters. The position peaked at $569K in Q1 2014. 78 funds tracked by Wall St. Rank hold PGNX as of Q3 2014.

  • Jacobs Levy Equity Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 88,400 Progenics Pharmaceuticals Inc shares in Q3 2014, an estimated $381K.
  • Jacobs Levy Equity Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Progenics Pharmaceuticals Inc position peaked at $569K in Q1 2014.
  • 78 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2014.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2014, filed 14 Nov 2014.